← Back to Search
Combination Therapy With Zidovudine And Didanosine Selects For Drug-resistant Human Immunodeficiency Virus Type 1 Strains With Unique Patterns Of Pol Gene Mutations.
R. Shafer, M. Kozal, M. Winters, A. Iversen, D. Katzenstein, M. Ragni, W. Meyer, P. Gupta, S. Rasheed, R. Coombs
Published 1994 · Biology, Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Drug resistance conferred by specific human immunodeficiency virus type 1 (HIV-1) pol gene mutations has been associated with clinical progression in HIV-infected patients receiving anti-retroviral therapy. This study examined drug susceptibilities and pol mutations of HIV-1 strains from patients treated for 1 year with zidovudine, didanosine (ddI), or zidovudine and ddI. Ten (42%) of 24 patients receiving combination therapy versus 8/26 (31%) receiving only zidovudine had HIV-1 strains with phenotypic zidovudine resistance or a zidovudine resistance pol mutation at codon 215 (P = .6). In contrast, a ddI resistance mutation at codon 74 was less common among patients receiving combination therapy (2/24) than among those receiving ddI only (17/26; P < .001). Two patients receiving combination therapy developed resistance to zidovudine and ddI; they had HIV strains with amino acid mutations at codons 62, 75, 77, 116, and 151. Combination therapy with zidovudine and ddI selects for zidovudine-resistant HIV-1 strains lacking a ddI resistance mutation and for multidrug-resistant strains containing novel pol mutations.
This paper references
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
B. Larder (1989)
Two drug combinations of zidovudine, didanosine, and recombinant interferon-alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
V. Johnson (1991)
Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors
J. Nunberg (1991)
Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.
B. Larder (1991)
Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells
R. Dornsife (1991)
Detection of Mutations Associated with Zidovudine Resistance in Human Immunodeficiency Virus by Use of the Polymerase Chain Reaction
Douglas D. Richman (1991)
3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
B. Larder (1992)
Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay
G. Mcleod (1992)
Zidovudine‐resistant and -sensitive HIV‐1 isolates from patients on drug therapy: in vitro studies evaluating level of replication‐competent viruses and cytopathogenicity
M. Tremblay (1992)
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.
C. Boucher (1992)
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients.
M. Kozal (1993)
Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells.
M. Smith (1993)
Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
P. Boyer (1993)
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
W. Gao (1993)
HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.
J. Balzarini (1993)
Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates.
R. Shafer (1993)
This paper is referenced by
A variety of key mutations in HIV reverse transcriptase (RT) have been associated with nucleoside reverse tran- scriptase inhibitor (NRTI) exposure, which give rise to a diverse range of effects in terms of altered drug suscep-
Veronica Miller (2021)
Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein.
J. Misasi (2021)
Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine
Y. Yasutake (2020)
The crosstalk between antiretrovirals pharmacology and HIV drug resistance
A. Giacomelli (2020)
Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: Insights for the dynamics and mechanisms of HIV-1 CA decomposition
Masayuki Amano (2019)
Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication
K. Maeda (2019)
The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans
Korea Republic (2019)
The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations
J. O. Maldonado (2018)
A study of profile of patients failing first line NACO recommended ART
Mahim Mittal (2018)
Prevalence of drug resistance mutations in HAART patients infected with HIV‐1 CRF06_cpx in Estonia
R. Avi (2016)
The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans
S. H. Wie (2015)
Horizontal gene transfer from human host to HIV-1 reverse transcriptase confers drug resistance and partly compensates for replication de fi cits
S. Megens (2014)
Horizontal gene transfer from human host to HIV-1 reverse transcriptase confers drug resistance and partly compensates for replication deficits.
S. Megens (2014)
In Vitro Cross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations
Zhufang Li (2013)
The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans
Activity Profiles & Mechanisms of Resistance of 3'-Azido-2',3'-Dideoxynucleoside Analog Reverse Transcriptase Inhibitors of HIV-1
Jeffrey D Meteer (2013)
Mechanistic insights into the role of secondary mutations of HIV-1 reverse transcriptase in the acquisition of antiretroviral drug resistance
Betancor Quintana (2013)
PRIMARY HIV-1 RESISTANCE - PERSISTENCE OF TRANSMITTED DRUG RESISTANCE MUTATIONS
V. Nikolić (2012)
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase
Tanyaradzwa P. Ndongwe (2012)
Managing Resistance to Anti-HIV Drugs
Anne-Mieke Vandamme (2012)
Use of Viral Resistance Patterns to Antiretroviral Drugs in Optimising Selection of Drug Combinations and Sequences
G. Moyle (2012)
Didanosine Enteric-Coated Capsule
S. Moreno (2012)
Antiretroviral Drug Resistance In Brazilian Children Infected By Human Immunodeficiency Virus Type 1
Beatriz Aparecida Passos Bismara (2012)
K70Q Adds High-Level Tenofovir Resistance to “Q151M Complex” HIV Reverse Transcriptase through the Enhanced Discrimination Mechanism
A. Hachiya (2011)
Mechanisms of Resistance to Antiviral Agents
R. Shafer (2011)
Novel Mechanisms of Resistance to HIV-1 Reverse Transcriptase (RT) Inhibitors: A Molecular and Clinical Characterization of Mutations in the Connection and RNase H Domains of RT
Jessica H. Brehm (2010)
Mechanisms by which Nonnucleoside Reverse Transcriptase Inhibitors Block HIV-1 Replication Alone and in Combination with other Reverse Transcriptase Inhibitors
J. Radzio (2010)
Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C
S. Margeridon-Thermet (2010)
Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA
N. Hasegawa (2009)
Clinical Implications of Reverse Transcriptase Inhibitor Resistance
K. Laethem (2009)
Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India
M. Vidya (2009)
Nucleoside Analogue Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase
Jerome Deval (2009)See more